1 / 2

Daratumumab : profil de tolérance et effets secondaires

Daratumumab : profil de tolérance et effets secondaires. EHA 2013 - D’après Lokhorst H et al., abstract S576 , actualisé. Daratumumab. Survie sans progression. 4-24 mg/kg (n = 12) Suivi médian  : 18,4 semaines (0-53) 0,005-2 mg/kg (n = 20) Suivi médian  : 8,6 semaines (0-29).

lixue
Télécharger la présentation

Daratumumab : profil de tolérance et effets secondaires

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Daratumumab : profil de tolérance et effets secondaires EHA 2013 - D’après Lokhorst H et al., abstract S576, actualisé

  2. Daratumumab • Survie sans progression 4-24 mg/kg (n = 12)Suivi médian : 18,4 semaines (0-53) 0,005-2 mg/kg (n = 20)Suivi médian : 8,6 semaines (0-29) p = 0,007 EHA 2013 - D’après Lokhorst H et al., abstract S576, actualisé

More Related